ERBB2 and breast carcinoma: The identification of subsets of breast cancers with overexpression of the HER-2/neu oncogene by IHC or amplification by fluorescence in situ hybridization (FISH) has led to the addition of targeted therapy for this subtype and improved survival [2, 3].